Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Edwards Lifesciences Reports Second Quarter Results

      Edwards Lifesciences logo. (PRNewsFoto/Edwards Lifesciences Corporation)

      News provided by

      Edwards Lifesciences Corporation

      Jul 26, 2018, 16:15 ET

      Share this article

      Share this article


      IRVINE, Calif., July 26, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2018.

      Second Quarter and Recent Highlights:

      • Sales grew 12 percent; underlying1 sales grew 10 percent
      • Global THVT sales grew 20 percent; underlying sales increased 12 percent
      • EPS grew 54 percent, aided by special items; adjusted1 EPS grew 15 percent
      • 2018 adjusted EPS guidance raised to $4.60 to $4.75 from $4.50 to $4.70
      • Received CE Mark for Cardioband tricuspid valve reconstruction system
      • CMS reopened National Coverage Determination for TAVR

      "We are pleased to report strong second quarter performance that delivered double-digit organic sales growth driven by robust sales of our innovative therapies. Adjusted sales grew 10 percent on an underlying basis, consistent with our expectations, and in-line with our projected 10 to 11 percent underlying sales growth for 2018," said Michael A. Mussallem, chairman and CEO.  "We experienced broad-based growth across the Edwards portfolio.  Looking forward, as structural heart disease is largely undertreated and underdiagnosed, we remain committed to increasing awareness and providing innovative lifesaving therapies, so that even more patients can benefit."

      Second Quarter 2018 Results

      Sales for the quarter ended June 30, 2018 were $944 million, up 12 percent.  Total adjusted sales were $972 million, up 10 percent over the second quarter last year. Diluted earnings per share for the quarter was $1.32 per share, while adjusted earnings per share grew 15 percent to $1.24.

      Transcatheter Heart Valve Therapy (THVT)

      For the quarter, the company reported THVT sales of $585 million, a 20 percent growth rate over the second quarter last year, or 12 percent on an underlying basis.  Globally, Edwards' average selling price increased slightly as a result of favorable country mix.  Estimated worldwide TAVR procedures continued to grow in the mid-teens, while Edwards' global growth was lower due to share decline outside the U.S.

      "Our SAPIEN 3 valve continues to demonstrate best-in-class clinical performance, and we look forward to the introduction of our SAPIEN 3 Ultra and CENTERA valves later this year to reinforce our leadership position," said Mussallem.  Separately, the company continues to anticipate data from the PARTNER 3 Trial to be presented at the ACC meeting in March of 2019, followed by FDA approval of the low-risk indication late that year.

      During the quarter, Edwards announced receipt of a CE Mark for the Cardioband tricuspid valve reconstruction system, and clinicians have begun treating patients. 

      Surgical Heart Valve Therapy and Critical Care

      Surgical Heart Valve Therapy sales for the quarter were $190 million, down 8 percent compared to the second quarter last year, or up 3 percent on an underlying basis.  Adjusted sales exclude the impact of the surgical heart valve consignment conversion.  Edwards' new premium aortic valve products drove underlying sales growth at a rate higher than total procedure growth.

      Critical Care sales were $169 million for the quarter, representing an increase of 15 percent versus last year, or 12 percent on an underlying basis.  This performance was driven by strong growth across product lines, led primarily by the HemoSphere advanced monitoring platform, aided by new group purchasing organization contracts in the U.S.

      Additional Financial Results

      For the quarter, the company's adjusted gross profit margin was 74.4 percent, compared to 75.3 percent in the same period last year. This reduction was driven by the impact from foreign exchange and continued investments in operations, partially offset by a more profitable product mix.

      Selling, general and administrative expenses increased 13 percent to $275 million for the quarter.  This increase was driven by personnel related expenses and the strengthening of the euro against the dollar.

      Research and development investments for the second quarter increased 15 percent to $154 million, or 16 percent of sales. This increase was primarily the result of continued investments in transcatheter heart valve therapy programs, including spending on clinical trials.

      The tax rate this quarter benefited from the settlement of tax audits and tax planning stemming from U.S. tax reform. Excluding the impact of special items, the tax rate would have been 10 percent.  Edwards now expects its 2018 tax rate, excluding special items, to be at the low end of its previous guidance range of 13 to 16 percent.

      Free cash flow for the second quarter was $87 million, defined as cash flow from operating activities of $140 million, less capital spending of $53 million.

      Cash, cash equivalents and short-term investments totaled $1.4 billion at June 30, 2018.  Total debt was $1.2 billion.

      Outlook

      Given the strong performance in the first half of 2018, Edwards remains confident in achieving the higher end of its sales guidance range of $3.5 to $3.9 billion.  Additionally, the company is raising its estimate for 2018 adjusted earnings per share to be between $4.60 and $4.75, from $4.50 to $4.70.

      For the third quarter 2018, at current foreign exchange rates, the company projects total sales to be between $900 million and $950 million, and adjusted EPS of $0.93 to $1.03.

      "We are confident in our outlook for continued strong sales growth, and we remain passionate about helping more patients around the world.  We continue to focus on driving organic growth with leading innovative technologies, while aggressively investing in our future.  Our foundation of leadership positions us well for continued longer-term success and greater shareholder value as we pursue multi-billion dollar market opportunities," said Mussallem.

      About Edwards Lifesciences         

      Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.

      Conference Call and Webcast Information          

      Edwards Lifesciences will be hosting a conference call today at 2:00 p.m. PT to discuss its second quarter results.  To participate in the conference call, dial (877) 704-2848 or (201) 389-0893.  For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13681143.  The call will also be available via live or archived webcast on the "Investor Relations" section of the Edwards web site at ir.edwards.com or www.edwards.com. A live stream and archived replay can also be accessed via mobile devices by downloading Edwards' IR App for iPhone and iPad or Android.

      This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "expect," "intend," "guidance," "outlook," "optimistic," "aspire," "confident"  or other forms of these words or similar expressions and include, but are not limited to, statements made by Mr. Mussallem, full year and third quarter 2018 financial guidance, expected timing of clinical trials, projected product approvals, and information in the Outlook section.  Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.  The company's forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.  If the company does update or correct one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections.

      Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements.  Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with the timing and pace of therapy adoption, particularly in THVT; unpredictability of the timing and impact of new product launches; competitive dynamics; the timing and extent of regulatory approvals and changes to reimbursement levels for the company's products; the company's success in developing new products and avoiding manufacturing and quality issues; the impact of currency exchange rates; the timing or results of R&D and clinical trials; unanticipated actions by the U.S. Food and Drug Administration and other regulatory agencies; unexpected litigation impacts or expenses; and other risks detailed in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2017. These filings, along with important safety information about our products, may be found at edwards.com.

      Edwards, Edwards Lifesciences, the stylized E logo, Cardioband, Edwards CENTERA, CENTERA, Edwards SAPIEN, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra, and HemoSphere are trademarks of Edwards Lifesciences Corporation.  All other trademarks are the property of their respective owners.

      ________________

      [1]

      "Adjusted" amounts are non-GAAP items.  Adjusted sales, or "underlying"  or "organic" growth rates, in this press release exclude foreign exchange fluctuations and a sales return reserve related to a surgical heart valve consignment conversion. Adjusted sales and "underlying" or "organic" growth rates also exclude the prior year positive impact of THVT stocking sales in Germany, and the negative impact of de-stocking. Adjusted earnings per share is a non-GAAP item computed on a diluted basis and in this press release excludes intellectual property litigation expenses, amortization of intellectual property, fair value adjustments to contingent consideration liabilities arising from acquisitions, a sales return reserve related to a surgical heart valve consignment conversion, impairment of long-lived assets, the impact of THVT stocking sales in Germany, and the impact from implementation of tax law changes and audit settlements. See the Non-GAAP Financial Information page and reconciliation tables below.

      EDWARDS LIFESCIENCES CORPORATION

      Unaudited Consolidated Statements of Operations

      (in millions, except per share data)



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,


      2018


      2017


      2018


      2017

      Net sales

      $

      943.7



      $

      841.8



      $

      1,838.5



      $

      1,725.3


      Cost of sales

      246.2



      211.1



      479.8



      426.7










      Gross profit

      697.5



      630.7



      1,358.7



      1,298.6










      Selling, general, and administrative expenses

      274.9



      243.8



      530.9



      473.4


      Research and development expenses

      154.1



      134.4



      297.3



      263.1


      Intellectual property litigation expenses

      5.5



      7.7



      11.2



      17.9


      Change in fair value of contingent consideration liabilities, net

      10.9



      3.1



      14.7



      4.2


      Other operating expenses, net

      —



      0.7



      —



      0.7










      Operating income

      252.1



      241.0



      504.6



      539.3










      Interest expense (income), net

      —



      1.4



      (0.8)



      3.8


      Special charges (gains), net

      —



      31.2



      (7.1)



      31.2


      Other expense (income), net

      1.1



      2.8



      (2.0)



      5.1










      Income before (benefit from) provision for income taxes

      251.0



      205.6



      514.5



      499.2










      (Benefit from) provision for income taxes

      (31.7)



      19.5



      25.2



      82.9










      Net income

      $

      282.7



      $

      186.1



      $

      489.3



      $

      416.3










      Earnings per share:








      Basic

      $

      1.35



      $

      0.88



      $

      2.33



      $

      1.97


      Diluted

      $

      1.32



      $

      0.86



      $

      2.28



      $

      1.93










      Weighted-average common shares outstanding:








      Basic

      209.5



      210.5



      209.8



      210.8


      Diluted

      214.0



      215.7



      214.5



      216.1










      Operating statistics








      As a percentage of net sales:








      Gross profit

      73.9

      %


      74.9

      %


      73.9

      %


      75.3

      %

      Selling, general, and administrative expenses

      29.1

      %


      29.0

      %


      28.9

      %


      27.4

      %

      Research and development expenses

      16.3

      %


      16.0

      %


      16.2

      %


      15.2

      %

      Operating income

      26.7

      %


      28.6

      %


      27.4

      %


      31.3

      %

      Income before (benefit from) provision for income taxes

      26.6

      %


      24.4

      %


      28.0

      %


      28.9

      %

      Net income

      30.0

      %


      22.1

      %


      26.6

      %


      24.1

      %









      Effective tax rate

      (12.6)

      %


      9.5

      %


      4.9

      %


      16.6

      %

      _________________

      Note: Numbers may not calculate due to rounding.

      EDWARDS LIFESCIENCES CORPORATION

      Unaudited Balance Sheets

      (in millions)



      June 30, 2018


      December 31, 2017

      ASSETS








      Current assets




      Cash and cash equivalents

      $

      1,226.4



      $

      818.3


      Short-term investments

      174.4



      519.2


      Accounts and other receivables, net

      520.1



      479.3


      Inventories, net

      568.1



      554.9


      Prepaid expenses

      69.9



      60.6


      Other current assets

      137.1



      116.9


      Total current assets

      2,696.0



      2,549.2






      Long-term investments

      470.4



      567.0


      Property, plant, and equipment, net

      770.2



      679.7


      Goodwill

      1,118.6



      1,126.5


      Other intangible assets, net

      466.0



      468.0


      Deferred income taxes

      130.1



      167.1


      Other assets

      34.8



      108.9






      Total assets

      $

      5,686.1



      $

      5,666.4






      LIABILITIES AND STOCKHOLDERS' EQUITY








      Current liabilities




      Accounts payable and accrued liabilities

      $

      584.0



      $

      770.3


      Short-term debt

      599.2



      598.0


      Contingent consideration liabilities

      —



      51.7


      Total current liabilities

      1,183.2



      1,420.0






      Long-term debt

      593.9



      438.4


      Contingent consideration liabilities

      199.0



      192.6


      Taxes payable

      263.3



      347.5


      Uncertain tax positions

      128.7



      164.6


      Other long-term liabilities

      153.8



      147.1






      Stockholders' equity




      Common stock

      214.0



      212.0


      Additional paid-in capital

      1,209.5



      1,166.9


      Retained earnings

      2,461.8



      1,962.1


      Accumulated other comprehensive loss

      (150.8)



      (132.7)


      Treasury stock, at cost

      (570.3)



      (252.1)


      Total stockholders' equity

      3,164.2



      2,956.2






      Total liabilities and stockholders' equity

      $

      5,686.1



      $

      5,666.4


      EDWARDS LIFESCIENCES CORPORATION
      Non-GAAP Financial Information

      To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses non-GAAP historical financial measures.  Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations).  The Company uses the term "adjusted sales" or "underlying growth rate" when referring to non-GAAP sales information, which excludes foreign exchange fluctuations, sales return reserves associated with transcatheter heart valve therapy ("THVT") product upgrades, the conversion to a consignment inventory system for surgical heart valves ("SHV"), and the positive impact of THVT stocking sales in Germany and the negative impact of de-stocking. The Company uses the term "adjusted" to also exclude intellectual property litigation income and expenses, amortization of intellectual property, fair value adjustments to contingent consideration liabilities arising from acquisitions, gains and losses from significant investments, impairments, litigation, the positive impact of THVT stocking sales in Germany and the negative impact of de-stocking, realignment expenses, sales return reserves and related costs associated with THVT product upgrades, the conversion to a consignment inventory system for SHV, charitable contributions to the Edwards Lifesciences Foundation, significant business development transactions, significant pension curtailment or settlement gains and losses, and the impact from implementation of tax law changes.

      Fluctuations in exchange rates impact the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of foreign exchange rate fluctuations from its sales growth provides investors a more useful comparison to historical financial results. The impact of foreign exchange rate fluctuations has been detailed in the "Reconciliation of Sales by Product Group and Region."

      Guidance for sales and sales growth rates is provided on an "underlying basis," and projections for diluted earnings per share, net income and growth, gross profit margin, taxes, and free cash flow are also provided on a non-GAAP basis as adjusted for the items identified above due to the inherent difficulty in forecasting such items.  The Company is not able to provide a reconciliation of the non-GAAP guidance to comparable GAAP measures due to the unknown effect, timing, and potential significance of special charges or gains, and management's inability to forecast charges associated with future transactions and initiatives.

      Management considers free cash flow to be a liquidity measure which provides useful information to management and investors about the amount of cash generated by business operations, after deducting payments for capital expenditures, which can then be used for strategic opportunities or other business purposes including, among others, investing in the Company's business, making strategic acquisitions, strengthening the balance sheet, and repurchasing stock.

      Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results, and evaluating current performance.  These non-GAAP financial measures are used in addition to, and in conjunction with, results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations by investors that, when viewed with its GAAP results, provide a more complete understanding of factors and trends affecting the Company's business and facilitate comparability to historical periods.

      Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.  A reconciliation of non-GAAP historical financial measures to the most comparable GAAP measure is provided in the tables below.

      The items described below are adjustments to the GAAP financial results in the reconciliations that follow:

      SHV Consignment Conversion - In the first and second quarters of 2018, the Company recorded a sales return reserve of $34.7 million ($30.8 million, net of related costs) and $28.4 million ($24.6 million, net of related costs), respectively, related to its conversion to a consignment inventory system for surgical heart valves.

      THVT Germany Stocking Sales - In the first quarter of 2017, the Company recorded $61.8 million in net stocking sales ($48.0 million, net of related costs) to customers in Germany, as these customers elected to purchase additional inventory in anticipation of a potential supply interruption resulting from intellectual property litigation.  In the second quarter of 2017, these customers consumed on a net basis $22.5 million ($17.9 million, net of related costs) of their stocking inventory.  In the first quarter of 2018, these customers consumed on a net basis $8.0 million ($6.0 million, net of related costs) of their stocking inventory.

      Intellectual Property Litigation Expenses - The Company incurred intellectual property litigation expenses of $5.7 million and $10.2 million in the first quarter of 2018 and 2017, respectively, and $5.5 million and $7.7 million in the second quarter of 2018 and 2017, respectively.

      Change in Fair Value of Contingent Consideration Liabilities, net - The Company recorded expenses related to changes in the fair value of its contingent consideration liabilities arising from acquisitions in the amount of $3.8 million and $1.1 million in the first quarter of 2018 and 2017, respectively, and $10.9 million and $3.1 million in the second quarter of 2018 and 2017, respectively.

      Amortization of Intellectual Property - The Company recorded amortization expense related to intellectual property in the amount of $0.6 million and $2.1 million in the first quarter of 2018 and 2017, respectively, and $0.7 million and $2.0 million in the second quarter of 2018 and 2017, respectively.

      Impairment of Long-lived Assets - The Company recorded a $31.2 million charge in the second quarter of 2017 related to the other-than-temporary impairment of one of its cost method investments and an associated long-term asset related to the Company's option to acquire this investee.

      Pension Curtailment Gain - The Company recorded a $7.1 million gain in the first quarter of 2018 related to the curtailment of its defined benefit plan resulting from the closure of its manufacturing plant in Switzerland.

      (Benefit from) Provision for Income Taxes - During the first quarter of 2018, the Company recorded a $24.0 million tax expense to adjust its estimated provisional amounts related to the implementation of U.S. tax law changes. During the second quarter of 2018, the Company recorded a $36.1 million tax benefit related to the settlement of tax audits and a $17.3 million benefit related to the reorganization of a foreign entity and adjustments to estimated provisional amounts resulting from the U.S. tax law changes. The income tax impact of the expenses and gains discussed above is based upon the items' forecasted effect upon the Company's full year effective tax rate.  Adjustments to forecasted items unrelated to these expenses and gains, as well as impacts related to interim reporting, will have an effect on the income tax impact of these items in subsequent periods.

      EDWARDS LIFESCIENCES CORPORATION

      Unaudited Reconciliation of GAAP to Non-GAAP Financial Information

      (in millions, except per share and percentage data)


      RECONCILIATION OF GAAP TO ADJUSTED OPERATING INCOME



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,


      2018


      2017


      2018


      2017

      GAAP Operating Income

      $

      252.1



      $

      241.0



      $

      504.6



      $

      539.3


      Growth Rate %

      4.6

      %




      (6.4)

      %











      Non-GAAP adjustments: (A)








      SHV consignment conversion

      24.6



      —



      55.4



      —


      THVT Germany stocking sales

      —



      17.9



      6.0



      (30.1)


      Intellectual property litigation expenses

      5.5



      7.7



      11.2



      17.9


      Change in fair value of contingent consideration liabilities, net

      10.9



      3.1



      14.7



      4.2


      Amortization of intellectual property

      0.7



      2.0



      1.3



      4.1


      Adjusted Operating Income

      $

      293.8



      $

      271.7



      $

      593.2



      $

      535.4


      Growth Rate %

      8.1

      %




      10.8

      %



      RECONCILIATION OF GAAP TO ADJUSTED NET INCOME



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,


      2018


      2017


      2018


      2017

      GAAP Net Income

      $

      282.7



      $

      186.1



      $

      489.3



      $

      416.3


      Growth Rate %

      51.9

      %




      17.5

      %











      Non-GAAP adjustments: (A)








      SHV consignment conversion

      24.6



      —



      55.4



      —


      THVT Germany stocking sales

      —



      17.9



      6.0



      (30.1)


      Intellectual property litigation expenses

      5.5



      7.7



      11.2



      17.9


      Change in fair value of contingent consideration liabilities, net

      10.9



      3.1



      14.7



      4.2


      Amortization of intellectual property

      0.7



      2.0



      1.3



      4.1


      Impairment of long-lived assets

      —



      31.2



      —



      31.2


      Pension curtailment gain

      —



      —



      (7.1)



      —










      (Benefit from) provision for income taxes








      Tax effect on reconciling items (B)

      (6.7)



      (15.7)



      (13.9)



      (8.8)


      Tax audit settlements

      (36.1)



      —



      (36.1)



      —


      Impacts from U.S. tax legislation

      (17.3)



      —



      6.7



      —


      Ongoing tax impact of non-fourth quarter items

      0.1



      —



      0.1



      —


      Adjusted Net Income

      $

      264.4



      $

      232.3



      $

      527.6



      $

      434.8


      Growth Rate %

      13.8

      %




      21.3

      %



      RECONCILIATION OF GAAP TO ADJUSTED DILUTED EARNINGS PER SHARE



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,


      2018


      2017


      2018


      2017

      GAAP Diluted Earnings Per Share

      $

      1.32



      $

      0.86



      $

      2.28



      $

      1.93


      Growth Rate %

      53.5

      %




      18.1

      %











      Non-GAAP adjustments: (A), (C)








      SHV consignment conversion

      0.09



      —



      0.21



      —


      THVT Germany stocking sales

      —



      0.06



      0.02



      (0.11)


      Intellectual property litigation expenses

      0.02



      0.03



      0.04



      0.06


      Change in fair value of contingent consideration liabilities, net

      0.05



      0.02



      0.07



      0.02


      Amortization of intellectual property

      —



      0.01



      0.01



      0.01


      Impairment of long-lived assets

      —



      0.10



      —



      0.10


      Pension curtailment gain

      —



      —



      (0.03)



      —










      (Benefit from) provision for income taxes








      Tax audit settlements

      (0.17)



      —



      (0.17)



      —


      Impacts from U.S. tax legislation

      (0.07)



      —



      0.03



      —


      Adjusted Diluted Earnings Per Share

      $

      1.24



      $

      1.08



      $

      2.46



      $

      2.01


      Growth Rate %

      14.8

      %




      22.4

      %



      _________________

      Note: Numbers may not calculate due to rounding.


      (A)

      See description of non-GAAP adjustments on the "Non-GAAP Financial Information" page.



      (B)

      The tax effect on non-GAAP adjustments is calculated based upon the impact of the relevant tax jurisdictions' statutory tax rates on the Company's estimated annual effective tax rate, or discrete rate in the quarter, as applicable.  The tax effect on the THVT Germany stocking sales adjustment is calculated using the global effective tax rate.



      (C)

      All amounts are tax effected, calculated based upon the impact of the relevant tax jurisdictions' statutory tax rates on the Company's estimated annual effective tax rate, or discrete rate in the quarter, as applicable.

      RECONCILIATION OF GAAP TO ADJUSTED GROSS PROFIT MARGIN



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,


      2018


      2017


      2018


      2017

      GAAP Gross Profit Margin

      73.9

      %


      74.9

      %


      73.9

      %


      75.3

      %









      Non-GAAP adjustments: (A)








      SHV consignment conversion

      0.4



      —



      0.5



      —


      THVT Germany stocking sales

      —



      0.1



      —



      —


      Amortization of intellectual property

      0.1



      0.3



      —



      0.2


      Adjusted Gross Profit Margin

      74.4

      %


      75.3

      %


      74.4

      %


      75.5

      %



      (A)

      See description of non-GAAP adjustments on the "Non-GAAP Financial Information" page.

      RECONCILIATION OF GAAP TO NON-GAAP TAX RATE



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,


      2018


      2017


      2018


      2017

      GAAP Tax Rate

      (12.6)

      %


      9.5

      %


      4.9

      %


      16.6

      %









      Non-GAAP adjustments: (A)








      Tax audit settlements

      12.5





      6.2



      —


      Impacts from U.S. tax legislation

      5.9





      (1.2)




      SHV consignment conversion

      2.7



      —



      1.1



      —


      THVT Germany stocking sales

      —



      0.9



      0.2



      (0.3)


      Intellectual property litigation expenses

      0.6



      0.6



      0.3



      0.4


      Change in fair value of contingent consideration liabilities, net

      0.5



      (0.1)



      —



      (0.1)


      Amortization of intellectual property

      0.1



      0.1



      —



      0.1


      Impairment of long-lived assets

      —



      2.2



      —



      0.7


      Non-GAAP Tax Rate

      9.7

      %


      13.2

      %


      11.5

      %


      17.4

      %



      (A)

      See description of non-GAAP adjustments on the "Non-GAAP Financial Information" page.

      EDWARDS LIFESCIENCES CORPORATION

      Unaudited Reconciliation of GAAP to Non-GAAP Financial Information

      ($ in millions)


      RECONCILIATION OF SALES BY PRODUCT GROUP AND REGION












      2018 Adjusted


      2017 Adjusted



      Sales by Product Group (QTD)


      2Q
      2018


      2Q
      2017


      Change


      GAAP

      Growth

       Rate*


      SHV
      Consignment
      Conversion

      Germany
      Stocking


      2Q 2018
      Adjusted
      Sales


      Germany
      Stocking


      FX

       Impact


      2Q 2017
      Adjusted
      Sales


      Underlying

      Growth

       Rate *

      Transcatheter Heart Valve Therapy


      $

      584.9



      $

      487.5



      $

      97.4



      20.0

      %


      $

      —


      $

      —



      $

      584.9



      $

      22.5



      $

      10.3



      $

      520.3



      12.4

      %

      Surgical Heart Valve Therapy


      190.3



      207.1



      (16.8)



      (8.1)

      %


      28.4


      —



      218.7



      —



      5.6



      212.7



      2.8

      %

      Critical Care


      168.5



      147.2



      21.3



      14.5

      %


      —


      —



      168.5



      —



      3.4



      150.6



      11.9

      %

      Total


      $

      943.7



      $

      841.8



      $

      101.9



      12.1

      %


      $

      28.4


      $

      —



      $

      972.1



      $

      22.5



      $

      19.3



      $

      883.6



      10.0

      %












      2018 Adjusted


      2017 Adjusted



      Sales by Product Group (YTD)


      YTD
      2Q
      2018


      YTD
      2Q
      2017


      Change


      GAAP

      Growth

       Rate*


      SHV
      Consignment
      Conversion

      Germany
      Stocking


      YTD 2Q
      2018
      Adjusted S
      ales


      Germany
      Stocking


      FX

      Impact


      YTD 2Q
      2017
      Adjusted
      Sales


      Underlying

      Growth

       Rate *

      Transcatheter Heart Valve Therapy


      $

      1,136.5



      $

      1,026.7



      $

      109.8



      10.7

      %


      $

      —


      $

      8.0



      $

      1,144.5



      $

      (39.3)



      $

      30.9



      $

      1,018.3



      12.4

      %

      Surgical Heart Valve Therapy


      369.8



      406.6



      (36.8)



      (9.1)

      %


      63.1


      —



      432.9



      —



      15.2



      421.8



      2.6

      %

      Critical Care


      332.2



      292.0



      40.2



      13.8

      %


      —


      —



      332.2



      —



      9.6



      301.6



      10.1

      %

      Total


      $

      1,838.5



      $

      1,725.3



      $

      113.2



      6.6

      %


      $

      63.1


      $

      8.0



      $

      1,909.6



      $

      (39.3)



      $

      55.7



      $

      1,741.7



      9.6

      %

































      2018 Adjusted


      2017 Adjusted



      Sales by Region (QTD)


      2Q
      2018


      2Q
      2017


      Change


      GAAP

      Growth
      Rate*


      SHV
      Consignment
      Conversion

      Germany
      Stocking


      2Q 2018
      Adjusted
      Sales


      Germany
      Stocking


      FX

      Impact


      2Q 2017
      Adjusted
      Sales


      Underlying

      Growth

       Rate *

      United States


      $

      512.1



      $

      478.9



      $

      33.2



      7.0

      %


      $

      28.4


      $

      —



      $

      540.5



      $

      —



      $

      —



      $

      478.9



      12.9

      %

      Europe


      228.0



      183.7



      44.3



      24.1

      %


      —


      —



      228.0



      22.5



      15.6



      221.8



      2.8

      %

      Japan


      102.6



      90.5



      12.1



      13.4

      %


      —


      —



      102.6



      —



      1.5



      92.0



      11.5

      %

      Rest of World


      101.0



      88.7



      12.3



      13.8

      %


      —


      —



      101.0



      —



      2.2



      90.9



      11.1

      %

      International


      431.6



      362.9



      68.7



      18.9

      %


      —


      —



      431.6



      22.5



      19.3



      404.7



      6.6

      %

      Total


      $

      943.7



      $

      841.8



      $

      101.9



      12.1

      %


      $

      28.4


      $

      —



      $

      972.1



      $

      22.5



      $

      19.3



      $

      883.6



      10.0

      %












      2018 Adjusted


      2017 Adjusted



      Sales by Region (YTD)


      YTD
      2Q
      2018


      YTD
      2Q
      2017


      Change


      GAAP

      Growth
      Rate*


      SHV
      Consignment
      Conversion

      Germany
      Stocking


      YTD 2Q
      2018
      Adjusted
      Sales


      Germany
      Stocking


      FX

      Impact


      YTD 2Q
      2017
      Adjusted
      Sales


      Underlying

      Growth

       Rate *

      United States


      $

      991.6



      $

      943.5



      $

      48.1



      5.1

      %


      $

      63.1


      $

      —



      $

      1,054.7



      $

      —



      $

      —



      $

      943.5



      11.8

      %

      Europe


      458.0



      444.7



      13.3



      3.0

      %


      —


      8.0



      466.0



      (39.3)



      44.5



      449.9



      3.6

      %

      Japan


      195.3



      169.8



      25.5



      15.0

      %


      —


      —



      195.3



      —



      5.4



      175.2



      11.5

      %

      Rest of World


      193.6



      167.3



      26.3



      15.7

      %


      —


      —



      193.6



      —



      5.8



      173.1



      11.8

      %

      International


      846.9



      781.8



      65.1



      8.3

      %


      —


      8.0



      854.9



      (39.3)



      55.7



      798.2



      7.1

      %

      Total


      $

      1,838.5



      $

      1,725.3



      $

      113.2



      6.6

      %


      $

      63.1


      $

      8.0



      $

      1,909.6



      $

      (39.3)



      $

      55.7



      $

      1,741.7



      9.6

      %

      ______________

      * Numbers may not calculate due to rounding.

      SOURCE Edwards Lifesciences Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.